Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 545 Squamous Cell Carcinoma of Head and Neck 281 Head and Neck Neoplasms 258 Lung Neoplasms 240 Uterine Cervical Neoplasms 182 Stomach Neoplasms 172 Esophageal Neoplasms 161 Nasopharyngeal Carcinoma 127 Urinary Bladder Neoplasms 117 Esophageal Squamous Cell Carcinoma 116 Neoplasms 115 Small Cell Lung Carcinoma 106 Ovarian Neoplasms 92 Breast Neoplasms 92 Neoplasm Metastasis 90 Cholangiocarcinoma 77 Carcinoma, Squamous Cell 76 Pancreatic Neoplasms 73 Biliary Tract Neoplasms 72 Oropharyngeal Neoplasms 57 Mesothelioma, Malignant 57 Carcinoma 55 Adenocarcinoma Of Esophagus 52 Recurrence 48 Parkinson Disease 4, Autosomal Dominant Lewy Body 47 Carcinoma, Ovarian Epithelial 46 Nasopharyngeal Neoplasms 41 Lymphoma 41 Adenocarcinoma of Lung 41 Triple Negative Breast Neoplasms 39

Interventions

pembrolizumab 2 enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sirtratumab vedotin 1 sacituzumab govitecan 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × Cisplatin × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡